Therapeutic Exploratory Study of CWP-0403

Inclusion Criteria: * Age of≥25 and \<75 with typeⅡ DM patients * Patients whose level of HbA1c is over 7.0% and less than 10% within 4weeks of screening registration * In spite of dietary and exercise treatment over 8weeks, the level of HbA1c is over 6.5% and less than 10%. * BMI between 20kg/㎡ and 40kg/㎡ * Out patients * patients who agree the trial participation with written informed consent Exclusion Criteria: * TypeⅠDM, Gestational diabetes. * Patients who are being treated with insulin * Fasting glucose level over 250mg/dL * Patients who are not compliant with dietary and exercise treatment during 8 weeks of screening period. (Evaluated "Bad" and worse) * Severe hepatic dysfunctions (i.e.: uncompensated hepatic cirrhosis)or AST or ALT level over 2.5times as high as UNL on screening visit. * Severe renal dysfunctions (i.e.: renal failure) or serum creatinine level over 1.5mg/dl * Severe cardiac dysfunction(i.e.: heart failure ) or history of myocardial infarction within 6months of screening * Chronic pulmonary disease or pulmonary infarction * Pancreatitis patients * Patients who are being treated for life threatening disease such as cancer, severe trauma or infection. * Uncontrollable diabetic complications(neuropathy, retinopathy, nephrosis) * Severe ketosis or experience of diabetic coma * Intestinal disease affecting digestion or absorption or history of GI dissection surgery except for appendectomy. * Pregnant, expecting to be pregnant or nursing female * Excessive alcohol consumption (Over 80g of alcohol/day: Over 1 bottle of 360ml Soju/day) * Participants of other clinical trials within 3 months of screening * Patients medicated with following non-concomitant medications Insulins or oral antidiabetics Oral (for more than 1 week) or IV corticosteroids (External and inhaled corticosteroids excluded) appetite suppressant exenatide or other GLP-1 analogues Other medications in development * Hypersensitive or intolerance to DPP4 inhibitory * patients who are decided to be inappropriate for this trial subject by the investigators